title: Prospects for advancing tuberculosis control efforts through novel therapies.
abstract: BACKGROUND
  Development of new, effective, and affordable tuberculosis (TB) therapies has been identified as a critical priority for global TB control. As new candidates emerge from the global TB drug pipeline, the potential impacts of novel, shorter regimens on TB incidence and mortality have not yet been examined.
  
  
  RESULTS
  We used a mathematical model of TB to evaluate the expected benefits of shortening the duration of effective chemotherapy for active pulmonary TB. First, we considered general relationships between treatment duration and TB dynamics. Next, as a specific example, we calibrated the model to reflect the current situation in the South-East Asia region. We found that even with continued and rapid progress in scaling up the World Health Organization's DOTS strategy of directly observed, short-course chemotherapy, the benefits of reducing treatment duration would be substantial. Compared to a baseline of continuing DOTS coverage at current levels, and with currently available tools, a 2-mo regimen introduced by 2012 could prevent around 20% (range 13%-28%) of new cases and 25% (range 19%-29%) of TB deaths in South-East Asia between 2012 and 2030. If effective treatment with existing drugs expands rapidly, overall incremental benefits of shorter regimens would be lower, but would remain considerable (13% [range 8%-19%] and 19% [range 15%-23%] reductions in incidence and mortality, respectively, between 2012 and 2030). A ten-year delay in the introduction of new drugs would erase nearly three-fourths of the total expected benefits in this region through 2030.
  
  
  CONCLUSIONS
  The introduction of new, shorter treatment regimens could dramatically accelerate the reductions in TB incidence and mortality that are expected under current regimens-with up to 2- or 3-fold increases in rates of decline if shorter regimens are accompanied by enhanced case detection. Continued progress in reducing the global TB burden will require a balanced approach to pursuing new technologies while promoting wider implementation of proven strategies.
authors.affiliation: Department of Population and International Health, Harvard School of Public Health, Boston, Massachusetts, United States of America. jsalomon@hsph.harvard.edu
authors.forename: Joshua A
authors.initials: JA
authors.lastname: Salomon
authors.forename: James O
authors.initials: JO
authors.lastname: Lloyd-Smith
authors.forename: Wayne M
authors.initials: WM
authors.lastname: Getz
authors.forename: Stephen
authors.initials: S
authors.lastname: Resch
authors.forename: María S
authors.initials: MS
authors.lastname: Sánchez
authors.forename: Travis C
authors.initials: TC
authors.lastname: Porco
authors.forename: Martien W
authors.initials: MW
authors.lastname: Borgdorff
mesh_terms: D000995:Antitubercular Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D001210:Asia, Southeastern / Q000453:epidemiology; D003140:Communicable Disease Control / Q000639:trends*; D023801:Directly Observed Therapy; D004334:Drug Administration Schedule; D015195:Drug Design; D006801:Humans; D015994:Incidence; D008962:Models, Theoretical; D010349:Patient Compliance; D055502:Secondary Prevention; D014376:Tuberculosis / Q000188:drug therapy* / Q000453:epidemiology / Q000517:prevention & control; D014944:World Health Organization
chemical_list: D000995:Antitubercular Agents